Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RVMD
REVOLUTION MEDICINES, INC.
NASDAQ
$207.88
▼ DOWN 6.00% (-13.27)

KEY STATISTICS

Market Cap$44.19 B
52w High$224.31
52w Low$37.88
Dividend Yield—
Frequency—
P/E-23.57
Volume2.00M
Shares Out.212.60M

COMPANY

LEADERSHIP

Mark A. Goldsmith
CHIEF EXECUTIVE
Mark A. Goldsmith

COMPENSATION 2026

Salary$689,167
Stock Awards$2,682,000
Incentive Plan Pay$651,800
All Other Comp.$7,000
Total$10,079,491

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 13, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
883

PRICE TARGET

Target High$320.00
Target Low$179.00
Target Median$248.00
Target Consensus$244.62

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$13.38M
NOV
4
WED

PRICE

$207.88 ▼ DOWN 6.00% (−$13.27)
$205$210$215$2209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM207.88

About Revolution Medicines, Inc.

https://www.revmed.com ↗

Revolution Medicines, Inc. is a clinical-stage oncology company developing targeted therapies against RAS-driven cancers, including SHP2, SOS1, mTORC1, and mutant KRAS inhibitors, with collaborations like Sanofi.

INDUSTRY

Biotechnology

A PRODUCT REVOLUTION MEDICINES, INC. IS KNOWN FOR

Daraxonrasib (RMC-6236)
Daraxonrasib (RMC-6236)

Daraxonrasib is Revolution Medicines' investigational oral RAS(ON) inhibitor in pivotal trials for pancreatic and non-small cell lung cancers, targeting a broad range of RAS mutations.

COMPETITORS

COMPETITOR
AMGN COMPARE
BBOT COMPARE
ERAS COMPARE
KURA COMPARE
RLAY COMPARE

Revenue by Products

IconPRODUCTQ2-2022Q3-2022Q4-2022Q1-2023
Collaboration Revenue Member$9.12M $3.36M ▼$15.33M ▲$7.01M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
447
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.05% · 6.4M
IBB
2.76% · 1.4M
SCHA
0.91% · 949.4K
XBI
1.36% · 735.1K
XWEH.F
0.58% · 393.4K
DFAC
0.11% · 240.3K
CGMM
1.20% · 203.6K
FCMO.TO
1.56% · 134.5K
QQQJ
2.26% · 123.7K
BBH
5.23% · 113.7K
JGRO
0.21% · 95.2K
H4ZJ.SG
0.09% · 86.2K
FXH
1.52% · 79.7K
GSLC
0.11% · 75.6K
JHMM
0.24% · 69.8K
CANC
6.07% · 61.8K
QMOM
2.25% · 45.7K
PB
PBPH
0.85% · 40.1K
MWRU.L
0.04% · 33.1K
WRDUSW.SW
0.04% · 30.1K
LABU
0.93% · 26.7K
IQSM
1.42% · 23.6K
BKLC
0.06% · 16.1K
RECS
0.06% · 15.7K
QYLU.L
0.35% · 15.6K
ZUH.TO
2.38% · 14.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
64.92%
HOLDERS
779
TOP 12 OF 779 · RANKED BY POSITION SIZE
Vanguard Group Inc
16.7M sh · $1.33B
Farallon Capital Management LLC
14.6M sh · $683.02M
Blackrock, Inc.
13.7M sh · $2.56B
Blackrock Inc.
13.4M sh · $520.39M
Janus Henderson Group Plc
12.3M sh · $980.04M
Fmr LLC
12.2M sh · $2.28B
Baker Bros. Advisors LP
11.4M sh · $2.14B
Darwin Global Management, Ltd.
10.6M sh · $2.05B
Wellington Management Group Llp
9.8M sh · $458.29M
Svennilson Peter
8.0M sh · $277.61M
Nextech Invest Ltd.
7.6M sh · $332.47M
Nextech Invest, Ltd.
7.6M sh · $1.42B

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: GENERAL COUNSEL
Cislini Jeff
Purchase · 26.6K shares
2026-08-21
★
OFFICER: GENERAL COUNSEL
Cislini Jeff
Sale · 25.8K shares
2026-08-21
★
OFFICER: GENERAL COUNSEL
Cislini Jeff
Sale · 2.5K shares
2026-08-21
★
OFFICER: GENERAL COUNSEL
Cislini Jeff
Sale · 4.5K shares
2026-08-21

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
OUTPERFORM 6
OVERWEIGHT 3
MARKET PERFORM 1
STRONG BUY 1
17 GRADES IN THE LAST 12 MONTHS
Bernstein MARKET PERFORM Truist Securities BUY Wedbush OUTPERFORM Guggenheim BUY RBC Capital OUTPERFORM Needham BUY Evercore ISI Group OUTPERFORM Mizuho OUTPERFORM

SECTORS PEERS

PEERPRICE
MRNA$137.99COMPARE
ROIV$34.71COMPARE
ASND$247.91COMPARE
BBIO$76.60COMPARE
EXEL$54.45COMPARE
BMRN$64.67COMPARE
MDGL$533.76COMPARE
SMMT$13.73COMPARE